ArticleSpinal cord2026
Impact of hypericin and Hypericum perforatum L. (St. John's Wort) extract on oxidative stress and neurotrophic factors during the acute phase of spinal cord injury in male rats.
Article in Spinal cord, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
designA randomized, controlled, experimental animal study.
objectivesThis study investigates the influence of Hypericum perforatum (St. John's Wort) and its active compound, hypericin, influence on oxidative stress markers and neurotrophic factor expression during the acute phase of SCI in male rats.
settingUniversity animal research facility equipped with dedicated surgical suites for SCI induction and controlled-environment housing for rodents.
methodsSCI was induced in Wistar rats through a contusion injury model. The treatment groups received either hypericin (50/100 mg/kg, i.p.) or Hypericum perforatum extract (50/100 mg/kg, i.p.) for two weeks. Motor function was evaluated with the Basso, Beattie, and Bresnahan (BBB) test, and nociceptive sensitivity was assessed using the tail flick test. Serum levels of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), nitric oxide (NO), and reactive oxygen species (ROS) were measured. Histological analysis of myelination was conducted using Luxol fast blue staining.
resultsSCI led to a significant decline in BBB scores, an increase in oxidative stress markers (NO, ROS), and a reduction in BDNF levels. Treatment with 100 mg/kg hypericin notably improved BBB scores (p < 0.00001), reduced NO and ROS levels (p < 0.0001), and increased BDNF expression compared to untreated SCI rats. Histological examination showed less demyelination in the treated groups, with hypericin demonstrating more pronounced effects than Hypericum perforatum extract.
conclusionHypericin exhibited strong neuroprotective properties by reducing oxidative stress, enhancing neurotrophic factor expression, and preserving myelin integrity. These findings highlight its potential as a therapeutic agent for reducing secondary damage following SCI.
Indexed as
Identifiers
42336995What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.